Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Laekna, Inc.

Equities

2105

KYG5340S1093

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:39 28/05/2024 BST 		5-day change 1st Jan Change
7.04 HKD +0.14% Intraday chart for Laekna, Inc. -9.16% -64.62%
05-23 US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
05-23 Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI

Business Summary

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.

Number of employees: 89

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 390,100,350 34,239,050 ( 8.777 %) 0 8.777 %

Shareholders

NameEquities%Valuation
OrbiMed Advisors Private Equity
15.32 %
59,774,230 15.32 % 47 M $
Xiang Yang Lu
12.72 %
49,603,870 12.72 % 39 M $
Ling Xie
10.67 %
41,618,770 10.67 % 33 M $
City of Ningbo
9.746 %
38,021,000 9.746 % 30 M $
Shanghai Gimpo Medical & Health Equity Investment Partnership
8.400 %
32,768,300 8.400 % 26 M $
Sdic China Merchants Investment Management Co., Ltd.
7.311 %
28,519,030 7.311 % 23 M $
Futu Trustee Ltd.
6.153 %
24,001,530 6.153 % 19 M $
Yanyuan Innovation Capital Group
5.136 %
20,034,370 5.136 % 16 M $
Beijing Anlong Venture Capital Fund LP
4.982 %
19,435,040 4.982 % 15 M $
Ningbo Ruichen Investment Partnership LP
4.335 %
16,911,780 4.335 % 13 M $

Company contact information

Laekna, Inc.

Zhangjiang Hi-Tech Park No. 987, Cailun Road

201203, Shanghai

+

http://www.laekna.com
address Laekna, Inc.(2105)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LAEKNA, INC. Stock Laekna, Inc.
-64.62% 351M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.78% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.37% 106B
BIONTECH SE Stock BioNTech SE
-11.03% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.56% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.93% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.82% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2105 Stock
  4. Company Laekna, Inc.